Three-year follow-up of 2-dose versus 3-dose HPV vaccine
Journal
Pediatrics
Journal Volume
147
Journal Issue
1
Pages
e20194035
Date Issued
2021
Author(s)
Bornstein J.
Roux S.
Petersen L.K.
Dobson S.R.
Pitisuttithum P.
Diez-Domingo J.
Schilling A.
Ariffin H.
Tytus R.
Rupp R.
Senders S.
Engel E.
Ferris D.
Kim Y.-J.
Kim Y.T.
Kurugol Z.
Bautista O.
Nolan K.M.
Sankaranarayanan S.
Saah A.
Luxembourg A.
Abstract
BACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9-14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16-26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36. METHODS: Girls received 2 (months 0 and 6 [0, 6]: n = 301; months 0 and 12 [0, 12]: n = 151) or 3 doses (months 0,2, and 6 [0, 2, 6]: n = 301); boys received 2 doses ([0, 6]: n = 301; [0, 12]: n = 150); and young women received 3 doses ([0, 2, 6]: n = 314) of 9vHPV vaccine. Anti-HPV geometric mean titers (GMTs) were assessed by competitive Luminex immunoassay (cLIA) and immunoglobulin G-Luminex immunoassay (IgG-LIA) through month 36. RESULTS: Anti-HPV GMTs were highest 1 month after the last 9vHPV vaccine regimen dose, decreased sharply during the subsequent 12 months, and then decreased more slowly. GMTs 2 to 2.5 years after the last regimen dose in girls and boys given 2 doses were generally similar to or greater than GMTs in young women given 3 doses. Across HPV types, most boys and girls who received 2 doses (cLIA: 81%-100%; IgG-LIA: 91%-100%) and young women who received 3 doses (cLIA: 78%-98%; IgG-LIA: 91%-100%) remained seropositive 2 to 2.5 years after the last regimen dose. CONCLUSIONS: Antibody responses persisted through 2 to 2.5 years after the last dose of a 2-dose 9vHPV vaccine regimen in girls and boys. In girls and boys, antibody responses generated by 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy through at least 2 years after the second dose. Copyright ? 2021 by the American Academy of Pediatrics
SDGs
Other Subjects
Wart virus vaccine; biological marker; virus antibody; Wart virus vaccine; abdominal pain; adolescent; adult; age distribution; allergic encephalitis; antibody response; antibody titer; Article; chemiluminescence immunoassay; child; cohort analysis; controlled study; dosage schedule comparison; drug dose regimen; drug response; drug withdrawal; epileptic state; female; follow up; geometry; heart arrest; human; human experiment; immunoassay; immunogenicity; immunoglobulin G luminex immunoassay; male; multicenter study; open study; priority journal; randomized controlled trial; school child; sex difference; single drug dose; transient urticaria; urticaria; verruca vulgaris; Alphapapillomavirus; blood; dose response; follow up; immunology; young adult; Adolescent; Adult; Alphapapillomavirus; Antibodies, Viral; Biomarkers; Child; Dose-Response Relationship, Immunologic; Female; Follow-Up Studies; Humans; Male; Papillomavirus Vaccines; Young Adult
Publisher
American Academy of Pediatrics
Type
journal article